FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib

Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses results from an exploratory analysis of EGFR mutation (EGFRm) dynamics in the Phase III FLAURA2 trial (NCT04035486), which assessed osimertinib with or without platinum-pemetrexed in patients with EGFR-mutant non-small cell lung cancer (NSCLC). Results suggest detected baseline plasma EGFRm is prognostic and predictive of enhanced progression-free survival (PFS) with osimertinib and chemotherapy, indicating potential utility in identifying patients benefiting most from combined therapy. However, on-treatment EGFRm clearance is only prognostic, with similar relative benefits observed across treatment arms. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.